



Final Report delivered under Option Agreement

13 July 2020 – Perth, Australia: PharmAust Limited (ASX:PAA), a clinical-stage oncology company, refers shareholders to the ASX announcement dated 18 April 2018 which details the key features of the Option Agreement.

<https://www.asx.com.au/asxpdf/20180418/pdf/43t99s457x47wn.pdf>

PharmAust confirms that the Final Report from the successful Phase II Canine Trial has now been delivered.

This announcement is authorised by the Board

Enquiries:

Dr Roger Aston
Executive Chairman and CEO
Tel: 0402 762 204
rogeraston@pharmaust.com

Dr Richard Mollard
Chief Scientific Officer
Tel: 0418 367 855
rmollard@pharmaust.com

About PharmAust (PAA):

PAA is a clinical-stage company developing targeted cancer therapeutics for humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. PAA's subsidiary, Epichem, is a successful contract medicinal chemistry company.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a key driver of cancer. MPL has been evaluated in Phase I clinical trials in humans and dogs; was well tolerated and produced a significant reduction in key prognostic biomarkers. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug in Phase II clinical trials.